Efficacy of salvage therapy with MTX-HOPE for elderly patients with heavily pretreated non-Hodgkin’s lymphoma

• Published in: Journal of Clinical and Experimental Hematopathology Vol. 60; no. 2; pp. 37 - 40
• Main Authors: Fukunaga, Akiko, Okamoto, Yoshio, Shibata, Sho, Inano, Shojiro, Takiuchi, Yoko, Yamamoto, Kazuyo, Tabata, Sumie, Kitano, Toshiyuki
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society for Lymphoreticular Tissue Research 01.01.2020; JSLRT
• Subjects: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Etoposide - therapeutic use; Female; Humans; Hydrocortisone - therapeutic use; Lymphoma, Non-Hodgkin - therapy; Male; Malignant lymphoma; Methotrexate - therapeutic use; MST-16; MTX-HOPE; Original; Piperazines - therapeutic use; salvage; Salvage Therapy - methods; sobuzoxane; Treatment Outcome; Vincristine - therapeutic use; MST-16; Malignant lymphoma; MTX-HOPE; salvage; sobuzoxane
• ISSN: 1346-4280; 1880-9952
• DOI: 10.3960/jslrt.19029

Methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide (MTX-HOPE) chemotherapy was originally reported in 2007 as a salvage regimen for relapsed or refractory non-Hodgkin’s lymphoma. To clarify the safety and efficacy of this regimen, we retrospectively analyzed patients at our institute. We analyzed 18 patients, including 16 with diffuse large B-cell lymphoma (DLBCL), one with follicular lymphoma (FL), and one with T-cell lymphoma. The median age at MTX-HOPE therapy was 79 (range: 68-87). Ten patients received more than 3 previous chemotherapy regimens. The median period from the initial treatment to the first MTX-HOPE administration was 53 months. No patient had severe renal dysfunction. The overall response rate was 78%, with 39% achieving CR and 39% achieving PR. The median OS and PFS after the initiation of MTX-HOPE were 10 months (range: 0.5-86 months) and 7 months (range: 0.2-86 months), respectively. The one-year OS rate was 44% and the two-year OS rate was 22%. The median number of treatment cycles was 7 (range: 1-46), and 6 patients received more than 10 cycles. Among eight patients who were over 80 years of age, 7 responded to the therapy, and the median OS and PFS of this subgroup were 19 months and 11 months, respectively. All patients tolerated the treatment well, mostly on an outpatient basis, except for one who died from infection and one who developed intracranial hemorrhage. MTX-HOPE may be a promising treatment option for elderly patients with refractory or relapsed malignant lymphoma.